News Sentiment

HRTX sentiment intelligence

Heron Therapeuti news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 44 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.41 Week of 10 Jul 2026
Weighted tone 44/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.5% over one week, +3.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from Brokerages

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -5.5% Price reacting lower
Trend fit Trend inactive 3.6% over four weeks
Fair value -76.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 27
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 6
Stock Titan 5
TradingKey 5
Investing.com 4
AD HOC NEWS 3
Moomoo 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 18
Analyst action 6
Regulatory and legal 2
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
AD HOC NEWS Direct company coverage

Heron Therapeutics updates investors on business progress as development pipeline remains the key va

Heron Therapeutics is progressing its drug portfolio, focusing on operational execution and a long-term strategy for treatments in oncology support and pain management. The company's stock valuation is closely tied to its clinical development pipeline, regulatory milestones, and

Tone
Positive 71/100
Event
Regulatory and legal
Published
07 Jul 2026 17:24
Source
AD HOC NEWS
Finviz Direct company coverage

HRTX - Heron Therapeutics Inc Options

This page provides a detailed financial overview of Heron Therapeutics Inc. (HRTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider and institutional ownership, and short inter

Tone
Negative 34/100
Event
Market update
Published
05 Jul 2026 15:11
Source
Finviz
Insider Monkey Direct company coverage

Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?

Heron Therapeutics (HRTX) faces a setback after a U.S. District Court ruled against it in Cinvanti patent litigation, leading H.C. Wainwright to lower its price target. The company plans to appeal the decision, asserting confidence in its legal arguments and intellectual property

Tone
Negative 37/100
Event
Analyst action
Published
30 Jun 2026 13:09
Source
Insider Monkey
TradingView Direct company coverage

Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Heron Therapeutics received a notice from Nasdaq on June 25, 2026, stating that its common shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company has 180 days, until December 22, 2026, to regain compliance by maintaining a cl

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:39
Source
TradingView
Market source Direct company coverage

Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision

Heron Therapeutics (HRTX) has seen its analyst fair value estimate cut from US$4.75 to US$3.00 per share following a Cinvanti patent decision that invalidated claims on two patents. This revision reflects legal risks, potential generic competition for Cinvanti (which accounts for

Tone
Negative 28/100
Event
Analyst action
Published
27 Jun 2026 19:06
Source
Market source
Moomoo Direct company coverage

Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification

Heron Therapeutics announced it received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement. The company has 180 calendar days, until December 23, 2024, to regain compliance, with a possible extension for another 180 days. Heron's common stoc

Tone
Negative 20/100
Event
Market update
Published
26 Jun 2026 20:10
Source
Moomoo
TradingView Direct company coverage

Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX)

This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting pa

Tone
Negative 36/100
Event
Earnings
Published
26 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Heron Therapeutics Inc Actuals & Estimates (BX:AXD2)

This article provides an overview of Heron Therapeutics Inc. (BX:AXD2) stock, including its current price, market capitalization, analyst forecasts, and historical highs and lows. It also details the company's recent financial performance, such as earnings per share and revenue,

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Heron Therapeutics, Inc. – NASDAQ:HRTX

This article provides financial data specifically regarding the enterprise value to revenue forward metric for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a stub or an entry on a financial data platform from TradingView, indicating that the value for this specific p

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:09
Source
TradingView
Stock Titan Direct company coverage

Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price

Heron Therapeutics (NASDAQ: HRTX) has received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, as its stock traded below this level for thirty consecutive days. The company has 180 calendar days, until December 22, 2026, to regain compl

Tone
Negative 24/100
Event
Market update
Published
25 Jun 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Heron Therapeutics, Inc. – NASDAQ:HRTX

This article provides financial data, specifically the "Price to sales forward" for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial snapshot from TradingView, offering a quick look at this metric, but without further details or analysis within the provided t

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
TradingView
AD HOC NEWS Direct company coverage

Heron Therapeutics Stock - long-term strategy under pressure after reverse split and Nasdaq warning

Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nasdaq's minimum bid price requirements and receiving a Nasdaq listing deficiency notice. The company, focused on pain management and

Tone
Negative 31/100
Event
Market update
Published
20 Jun 2026 20:37
Source
AD HOC NEWS
TradingKey Direct company coverage

Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Heron Therapeutics Inc (HRTX) by business segment and region for the reported fiscal years, updated on April 6. It highlights that CINVANTI, SUSTOL, ZYNRELEF, and APONVIE are the primary revenue contributors, with CINVANTI ac

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Heron Therapeutics Inc (HRTX) regarding its dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and that there is no historical data available for both dividend payments and

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:39
Source
TradingKey
Investing.com Direct company coverage

Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting

Heron Therapeutics (NASDAQ:HRTX) stockholders approved all six proposals at their 2026 Annual Meeting on June 11, including the election of seven directors and the ratification of their accounting firm. Key amendments to equity incentive and employee stock purchase plans were als

Tone
Negative 40/100
Event
Market update
Published
17 Jun 2026 19:39
Source
Investing.com
AD HOC NEWS Direct company coverage

Heron Therapeutics Stock - Shareholders back equity plans and tax measure at 2026 meeting

Heron Therapeutics shareholders approved all proposals at their 2026 annual meeting, including significant increases to equity and employee stock purchase plans and a tax benefits preservation plan. This approval provides management with greater flexibility in using stock-based c

Tone
Positive 63/100
Event
Regulatory and legal
Published
17 Jun 2026 16:10
Source
AD HOC NEWS
Stock Titan Direct company coverage

Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes

Heron Therapeutics' EVP and CFO, Ira Duarte, engaged in routine equity compensation activity, exercising 12,500 restricted stock units on June 16, 2026. To cover tax obligations, Duarte disposed of 3,555 common shares at $0.38 per share. Following these transactions, Duarte direc

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 15:10
Source
Stock Titan
TradingKey Direct company coverage

Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis

Heron Therapeutics Inc (HRTX) has a current financial score of 7.51, ranking 112 out of 388 in its industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71M, and its net profit sa

Tone
Negative 39/100
Event
Earnings
Published
16 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis

Heron Therapeutics Inc (HRTX) has a current valuation score of 8.03, ranking 178 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -2.11, significantly different from its recent high and low. Data for P/B, P/S, and P/CF ratios have not been d

Tone
Negative 41/100
Event
Market update
Published
16 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Heron Therapeutics Inc (HRTX), evaluating its volatility, financial risk, and investment risk. The company's risk assessment score is 4.44, ranking 80 out of 388 in the Biotechnology & Medical Research industry, with a beta of 1.62 indi

Tone
Negative 39/100
Event
Market update
Published
16 Jun 2026 21:10
Source
TradingKey
Investing.com South Africa Direct company coverage

Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com

Heron Therapeutics stockholders approved all six proposals at their 2026 Annual Meeting, including the election of seven directors and the ratification of their accounting firm. They also approved executive compensation and two plan amendments related to equity incentives and emp

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan

Heron Therapeutics stockholders approved several key proposals at their 2026 Annual Meeting on June 11, 2026. This included electing seven directors, ratifying their auditor, and approving executive compensation on an advisory basis. Shareholders also significantly increased the

Tone
Positive 58/100
Event
Market update
Published
16 Jun 2026 19:10
Source
Stock Titan
Seeking Alpha Direct company coverage

Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)

Heron Therapeutics faces a significant setback after a court ruled its Cinvanti patents invalid, jeopardizing its main revenue source. The growth of Zynrelef is insufficient to compensate for potential Cinvanti losses, while other products like Aponvie and Sustol have not met exp

Tone
Negative 5/100
Event
Analyst action
Published
10 Jun 2026 12:38
Source
Seeking Alpha
Stock Titan Direct company coverage

Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares

Heron Therapeutics' EVP, William P. Forbes, exercised 12,500 restricted stock units (RSUs) into common shares on June 6, 2026, as part of his compensation, incurring no cash cost. Following this transaction, Forbes directly holds 221,611 common shares and 12,500 RSUs that will ve

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jun 2026 14:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents

Heron Therapeutics has announced its intention to appeal a U.S. District Court ruling that invalidated patents covering its CINVANTI drug. The company will pursue this appeal to the U.S. Court of Appeals for the Federal Circuit to protect its intellectual property amidst potentia

Tone
Negative 35/100
Event
Market update
Published
03 Jun 2026 23:39
Source
The Globe and Mail
Moomoo Direct company coverage

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2

H.C. Wainwright has reiterated its Buy rating for Heron Therapeutics (HRTX.US) but has reduced the target price for the company's stock to $2. This adjustment reflects a revised outlook from the analyst firm while maintaining a positive long-term stance on the company's prospects

Tone
Negative 37/100
Event
Analyst action
Published
03 Jun 2026 18:39
Source
Moomoo